# A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes

> **NCT01427699** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 7 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** T2-18C3 therapeutic antibody

## Key facts

- **NCT ID:** NCT01427699
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-30
- **Primary completion:** 2012-10-31
- **Final completion:** —
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01427699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01427699, "A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01427699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*